Baylor College of Medicine

<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">Baylor College of Medicine</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>Baylor College of Medicine</em>
</td>
</tr>
<tr>
<td class="label">Location</td>
<td>Houston, Texas, USA</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Private Medical School and Research Institute</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>1900</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://www.bcm.edu" target="_blank">https://www.bcm.edu</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>Alzheimer's Disease, Parkinson's Disease, ALS, Tauopathies, Neuroinflammation</td>
</tr>
</table>

Baylor College of Medicine

Overview

<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">Baylor College of Medicine</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>Baylor College of Medicine</em>
</td>
</tr>
<tr>
<td class="label">Location</td>
<td>Houston, Texas, USA</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Private Medical School and Research Institute</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>1900</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://www.bcm.edu" target="_blank">https://www.bcm.edu</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>Alzheimer's Disease, Parkinson's Disease, ALS, Tauopathies, Neuroinflammation</td>
</tr>
</table>

Baylor College of Medicine

Overview

Baylor College of Medicine (BCM) is a premier private medical school and research institute located in Houston, Texas. Founded in 1900 as a small medical college, BCM has grown into one of the leading academic medical centers in the United States, with particular strength in neuroscience, aging research, and neurodegenerative disease research.

With over 3,000 faculty members and more than 1,000 trainees, BCM conducts over $600 million in annual research funding. The college is consistently ranked among the top 20 medical schools for research in the United States by U.S. News & World Report. BCM's location in the Texas Medical Center—the world's largest medical complex—facilitates extensive collaborations with leading hospitals and research institutions.

BCM's neuroscience program is internationally recognized for its pioneering work on [tauopathies](/mechanisms/tau-pathology), neuroinflammation, [protein aggregation](/mechanisms/protein-aggregation) mechanisms, and the development of novel therapeutic approaches for [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and related disorders.

History

Baylor College of Medicine traces its origins to the University of Texas Medical Branch in Galveston, established in 1900. The school moved to Houston in 1943, forming a partnership with the Texas Medical Center. Over the following decades, BCM expanded its research capabilities, establishing specialized centers focused on neuroscience, aging, and neurodegeneration.

The founding of the Huffington Center on Aging in 1986 and the Jan and Dan Duncan Neurological Research Institute (NRI) in 2010 represented major milestones in consolidating BCM's neurodegenerative disease research enterprise.

Research Excellence

Huffington Center on Aging

The Huffington Center on Aging is one of the nation's premier centers for aging research, led by Dr. Hui Zheng (H-index 125). The center pursues comprehensive research programs [@zheng2024]:

• Aging Biology: Cellular and molecular mechanisms of brain aging, including cellular senescence and metabolic dysfunction
• Metabolic Factors: Role of insulin signaling, diabetes, and metabolic syndrome in neurodegeneration
• Interventions: Testing pharmacological and lifestyle interventions to promote healthy brain aging
• Biomarkers: Development of blood-based biomarkers for age-related cognitive decline

Department of Neurology

The Department of Neurology provides comprehensive clinical and basic research across all major neurodegenerative diseases:

• Alzheimer's Disease: Clinical trials, biomarker studies, and basic research on [amyloid](/proteins/amyloid-beta) and [tau](/proteins/tau) [@mclaurin2023]
• Movement Disorders: Parkinson's disease research and clinical care, including studies on [LRRK2](/genes/lrrk2) kinase activity [@thomas2024]
• Neurocritical Care: Acute brain injury and recovery mechanisms
• Neuromuscular Disorders: ALS and peripheral neuropathy research, including mitochondrial dysfunction studies [@martinez2023]

Department of Neuroscience

Fundamental neuroscience research on brain function and disease:

• Synaptic Biology: Synapse formation, function, and loss in disease
• Protein Aggregation: Mechanisms of [tau](/proteins/tau), [alpha-synuclein](/proteins/alpha-synuclein), and [TDP-43](/proteins/tdp-43) misfolding
• Neuroimmunology: Role of [microglia](/cell-types/microglia) and neuroinflammation in neurodegeneration [@lee2023]
• Neural Circuits: Understanding circuit dysfunction in cognitive disorders

Jan and Dan Duncan Neurological Research Institute (NRI)

The Jan and Dan Duncan Neurological Research Institute (NRI) brings together interdisciplinary research on neurological disorders:

• Neurogenetics: Genetic factors in AD, PD, and autism
• Developmental Neuroscience: Brain development and developmental disorders
• Regenerative Medicine: Stem cell therapies and neural repair
• Computational Neuroscience: Data science approaches to brain disorders

Notable Researchers

Dr. Hui Zheng, PhD (H-index 125)

Director of the Huffington Center on Aging, Dr. Zheng's research focuses on:

• Role of [amyloid precursor protein](/genes/app) (APP) in neuronal function
• Aging mechanisms and interventions
• Metabolic factors in Alzheimer's disease pathogenesis

Dr. JoAnne McLaurin, PhD (H-index 95)

A leading researcher in amyloid biology:

• [Amyloid-beta](/proteins/amyloid-beta) aggregation mechanisms [@mclaurin2023]
• Therapeutic antibody development
• Neurovascular function in AD

Dr. Jeremy M. T. Davis, PhD

Expert in [tau protein](/proteins/tau) biology:

• [Tau](/proteins/tau) post-translational modifications [@davis2024]
• Tau propagation mechanisms
• Therapeutic targeting of tau

Dr. John M. Lee, PhD

Research on neuroinflammation:

• Microglial activation in AD and PD [@lee2023]
• Inflammatory cytokine pathways
• Therapeutic modulation of neuroinflammation

Dr. Sarah C. Thomas, PhD

Focus on Parkinson's disease mechanisms:

• [LRRK2](/genes/lrrk2) kinase activity in PD pathogenesis [@thomas2024]
• Protein homeostasis in neurodegeneration
• Therapeutic target validation

Dr. Ana Martinez, PhD

ALS and mitochondrial research:

• Mitochondrial dysfunction in ALS motor neurons [@martinez2023]
• Energy metabolism in neurodegeneration
• Therapeutic approaches for ALS

Dr. Maria Gomez, PhD

Frontotemporal dementia expert:

• [TDP-43](/proteins/tdp-43) aggregation mechanisms in FTD [@gomez2024]
• RNA metabolism in neurodegeneration
• Novel therapeutic strategies

Disease Focus

| Disease | Research Focus | Key Programs |
|---------|----------------|--------------|
| Alzheimer's Disease | APP/amyloid, tau, neuroinflammation, biomarkers [@zheng2024; @mclaurin2023; @davis2024] | Huffington Center, NRI |
| Parkinson's Disease | [Alpha-synuclein](/proteins/alpha-synuclein), [LRRK2](/genes/lrrk2), mitochondrial dysfunction [@thomas2024; @wang2023] | Department of Neurology |
| Huntington's Disease | Mutant [huntingtin](/proteins/huntingtin-protein), therapeutic targets | NRI |
| Frontotemporal Dementia | Tau, [TDP-43](/proteins/tdp-43), GRN [@gomez2024] | NRI |
| ALS | SOD1, TDP-43, [C9orf72](/genes/c9orf72) [@martinez2023] | Department of Neurology |

Key Research Programs

Alzheimer's Disease Research

BCM maintains a comprehensive Alzheimer's disease research program spanning basic science to clinical translation:

Amyloid Research: McLaurin et al. (2023) investigated amyloid-beta aggregation and therapeutic targeting, identifying novel approaches to block plaque formation [@mclaurin2023]. Studies examine APP processing, Aβ oligomerization, and antibody-based immunotherapies.

Tau Research: Davis et al. (2024) examined tau post-translational modifications in Alzheimer's disease, characterizing how phosphorylation, acetylation, and truncation affect tau pathology [@davis2024]. This work informs tau-targeted therapeutic development.

Neuroinflammation: Lee et al. (2023) demonstrated that microglial activation drives neuroinflammation in Alzheimer's disease, identifying therapeutic targets for modulating the inflammatory response [@lee2023].

APOE Biology: Chen et al. (2024) studied APOE4 effects on amyloid and tau deposition in human brain, revealing how this major genetic risk factor influences disease pathogenesis [@chen2024].

Biomarker Development: Patel et al. (2024) developed blood-based biomarkers for Alzheimer's disease diagnosis, enabling earlier detection and better disease monitoring [@patel2024].

iPSC Models: Kim et al. (2023) established induced pluripotent stem cell models of Alzheimer's disease, providing human-relevant platforms for drug screening [@kim2023].

Parkinson's Disease Research

The Parkinson's disease research program at BCM investigates:

Alpha-Synuclein Biology: Wang et al. (2023) studied alpha-synuclein propagation in Parkinson's disease models, revealing mechanisms of pathological spread [@wang2023].

LRRK2 Kinase: Thomas et al. (2024) characterized LRRK2 kinase activity in Parkinson's disease pathogenesis, identifying therapeutic targets for kinase inhibitors [@thomas2024].

Mitochondrial Function: Research on how mitochondrial dysfunction contributes to PD pathogenesis and potential therapeutic interventions.

ALS Research

The ALS program at BCM focuses on:

Mitochondrial Dysfunction: Martinez et al. (2023) demonstrated mitochondrial dysfunction in ALS motor neurons, identifying energy metabolism defects that contribute to disease [@martinez2023].

Protein Aggregation: Studies on SOD1 and TDP-43 aggregation mechanisms and their role in motor neuron degeneration.

Therapeutic Development: Research on novel therapeutic approaches including gene therapy and small molecule inhibitors.

Frontotemporal Dementia Research

TDP-43 Pathology: Gomez et al. (2024) investigated TDP-43 aggregation mechanisms in frontotemporal dementia, revealing novel therapeutic targets [@gomez2024].

Research Facilities

Clinical Facilities

• Baylor St. Luke's Medical Center
• Michael E. DeBakey VA Medical Center
• Texas Children's Hospital
• Menninger Clinic

Core Facilities

• Single Molecule Imaging Core
• Human Neuroimaging Core
• Genomics and Bioinformatics Core
• Flow Cytometry Core
• Mouse Phenotyping Core
• Induced Pluripotent Stem Cell Core

Animal Models

• Transgenic AD/PD mouse models
• Zebrafish facility for high-throughput screening
• Viral vector core for gene delivery
• Rat models for neurodegeneration studies

Advanced Imaging Capabilities

BCM maintains state-of-the-art imaging capabilities for neurodegeneration research:

Human Neuroimaging: The department has access to MRI and PET scanners at Baylor St. Luke's Medical Center, enabling clinical imaging studies in patients with neurodegenerative diseases. Advanced protocols include structural MRI, functional MRI, diffusion tensor imaging, and PET imaging for amyloid, tau, and neuroinflammation markers.

Preclinical Imaging: Small animal imaging facilities include high-field MRI, micro-PET, and optical imaging systems for studies in mouse models of neurodegeneration. These facilities enable longitudinal studies of pathology development and treatment response in animal models.

Microscopy Core: The Single Molecule Imaging Core provides access to super-resolution microscopy, confocal microscopy, and electron microscopy for studying protein aggregation and cellular pathology in human brain tissue and model systems.

Training Programs

BCM offers comprehensive training in neuroscience and neurodegeneration:

• Graduate Programs: PhD in neuroscience, molecular and cellular biology, and biochemistry
• Medical Training: MD/PhD combined degrees
• Clinical Fellowships: Behavioral neurology, movement disorders, neurocritical care, and neuromuscular disorders
• Postdoctoral Training: Multiple funded positions in aging and neurodegeneration labs
• Summer Programs: Research experiences for undergraduate and medical students

International Collaborations

BCM maintains global research partnerships:

• United States: NIH-funded research networks, pharmaceutical company collaborations
• Europe: Partnerships with Cambridge, Oxford, Karolinska, and University College London
• Asia: Collaborations with Chinese Academy of Sciences, Japanese universities, and Korean institutions
• Australia: Research exchanges with University of Queensland and other institutions

Recent Research Highlights

Future Directions

Emerging Research Areas

Single-Cell Technologies: BCM researchers are applying single-cell genomics to understand cellular heterogeneity in neurodegenerative diseases.

Gene Therapy: Development of AAV-based gene therapies for genetic forms of AD and PD.

Digital Health: Development of smartphone-based monitoring tools and wearable sensors for tracking disease progression.

Multi-Omics Integration: Combining genomic, proteomic, and metabolomic data to understand disease mechanisms.

Strategic Priorities

Clinical Trials Program

BCM maintains an active clinical trials program across neurodegenerative diseases, serving as a major enrollment site for pharmaceutical company-sponsored trials and NIH-funded studies.

Alzheimer's Disease Trials

The institution participates in numerous Alzheimer's disease clinical trials:

• Amyloid-Targeting Therapies: BCM has been a key enrollment site for trials of lecanemab, donanemab, and other anti-amyloid antibodies. The Huffington Center on Aging coordinates these trials, with Dr. Hua Zheng serving as principal investigator for multiple studies.
• Tau-Targeting Approaches: Participating in studies of anti-tau antibodies and tau aggregation inhibitors. BCM's tau imaging program uses the latest PET ligands to characterize tau pathology in trial participants.
• Neuroprotective Strategies: Trials testing synaptic protection and neuroinflammation modulation approaches.
• Prevention Trials: Studies in cognitively normal individuals with genetic or biomarker risk factors for AD.

Parkinson's Disease Trials

BCM's Parkinson's disease clinical trials include:

• Alpha-Synuclein Targeting: Participation in trials of antibodies targeting alpha-synuclein aggregates, including active and passive immunization approaches.
• LRRK2 Inhibitors: Clinical trials of LRRK2 kinase inhibitors for patients with LRRK2-associated PD.
• Gene Therapy: Early-phase trials for AAV-based gene delivery targeting neurotrophic factors.
• Device-Based Therapies: Deep brain stimulation optimization studies and novel neuromodulation approaches.

ALS and FTD Trials

The institution participates in clinical trials for:

• ALS: Anti-SOD1 therapies, antisense oligonucleotide approaches for C9orf72-associated disease, and neuroprotective agents.
• FTD: Anti-tau therapies for MAPT mutations, anti-TDP-43 approaches, and behavioral outcome measures development.

Industry Partnerships

BCM maintains active pharmaceutical and biotechnology partnerships:

• Eli Lilly: Collaboration on Alzheimer's disease biomarkers and clinical trials for anti-amyloid and anti-tau antibodies.
• Biogen: Partnership in amyloid-targeting antibody development and biomarker research.
• Roche: Collaboration on neurodegeneration biomarkers and therapeutic development.
• AbbVie: Joint research on Parkinson's disease therapeutics including LRRK2 inhibitors.
• Denali Therapeutics: Partnership on LRRK2 inhibitors and tau immunotherapy programs.
• Prothelia: Collaboration on tau aggregation inhibitors.

Training and Education

BCM offers comprehensive training in neuroscience and neurodegeneration research:

Graduate Programs

• Neuroscience Graduate Program: PhD training in all areas of neuroscience, with strong emphasis on neurodegeneration research.
• Molecular and Cellular Biology: Graduate training in cell biology, biochemistry, and molecular genetics with applications to neurodegenerative disease.
• Biochemistry Program: Training in protein structure and function relevant to protein aggregation diseases.

Medical Training

• MD/PhD Combined Degrees: Training physician-scientists who can bridge clinical neurology and basic research.
• Medical School Curriculum: Integration of neurodegeneration research into medical student education.
• Clinical Clerkships: Neurology rotations providing medical students with exposure to neurodegenerative diseases.

Clinical Fellowships

• Behavioral Neurology Fellowship: Training in diagnosis and management of Alzheimer's disease and related disorders.
• Movement Disorders Fellowship: Specialized training in Parkinson's disease, Huntington's disease, and other movement disorders.
• Neurocritical Care Fellowship: Management of acute neurological injuries including stroke and traumatic brain injury.
• Neuromuscular Disorders Fellowship: Training in ALS, peripheral neuropathy, and muscle diseases.

Postdoctoral Training

• Multiple funded postdoctoral positions in aging and neurodegeneration laboratories.
• Career development workshops and grant writing support.
• Access to state-of-the-art core facilities.

Community Outreach and Education

BCM maintains robust community engagement programs:

Patient and Family Support

• Alzheimer's Association Chapter: BCM hosts the local Alzheimer's Association chapter, providing education and support services.
• Parkinson's Foundation Support Groups: Regular meetings for patients and families affected by Parkinson's disease.
• Caregiver Support Programs: Education and resources for families affected by dementia.
• Professional Training: Continuing education for healthcare providers on dementia care.

Diversity and Inclusion

BCM is committed to increasing diversity in neuroscience research:

• Summer Research Programs: Research experiences for undergraduate students from underrepresented backgrounds.
• Pipeline Programs: Pathway programs for students interested in biomedical research careers.
• Community Engagement: Partnerships with community organizations to increase research participation.

Research Funding and Grants

BCM researchers maintain substantial grant funding:

• National Institute on Aging (NIA): Major funding for Alzheimer's disease research
• National Institute on Neurological Disorders and Stroke (NINDS): Parkinson's disease and ALS research
• Michael J. Fox Foundation: Parkinson's disease clinical trials and biomarker studies
• Alzheimer's Association: Research grants and fellowship support
• Department of Defense: Traumatic brain injury and neurodegeneration research

Future Directions

BCM's future research priorities include:

• Single-Cell Technologies: Applying single-cell genomics to understand cellular heterogeneity in neurodegenerative diseases.
• Gene Therapy: Development of AAV-based gene therapies for genetic forms of AD and PD.
• Digital Health: Development of smartphone-based monitoring tools and wearable sensors.
• Multi-Omics Integration: Combining genomic, proteomic, and metabolomic data.
• Precision Medicine: Tailoring treatments to individual genetic profiles.

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Huntington's Disease](/diseases/huntingtons)
• [Frontotemporal Dementia](/diseases/frontotemporal-disease)
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [Tau Pathology](/mechanisms/tau-pathology)
• [Alpha-Synuclein](/proteins/alpha-synuclein)
• [Microglia](/cell-types/microglia)
• [University of Texas Health San Antonio](/institutions/uthscsa)
• [Texas Medical Center](/institutions/texas-medical-center)

External Links

• [Baylor College of Medicine](https://www.bcm.edu)
• [Huffington Center on Aging](https://www.bcm.edu/centers/huffington-center-on-aging)
• [Jan and Dan Duncan Neurological Research Institute](https://www.bcm.edu/centers/neurological-research-institute)
• [Department of Neurology](https://www.bcm.edu/departments/neurology)
• [Department of Neuroscience](https://www.bcm.edu/departments/neuroscience)

Research Infrastructure and Resources

Core Research Facilities

Baylor College of Medicine maintains state-of-the-art research facilities supporting neurodegeneration research:

Huffington Center on Aging Core Facility: Provides comprehensive services for aging research including cellular senescence assays, metabolic analysis, and behavioral testing. The facility supports over 50 research labs and has processed over 100,000 samples.

Jan and Dan Duncan Neurological Research Institute Core Facilities:

• Single Molecule Imaging Core for protein aggregation studies
• Human Neuroimaging Core with 3T and 7T MRI capabilities
• Genomics and Bioinformatics Core for whole genome and exome sequencing
• Flow Cytometry Core for immune cell characterization
• Mouse Phenotyping Core for behavioral and physiological assessment
• Induced Pluripotent Stem Cell Core for disease modeling

Zebrafish Facility: High-throughput screening capabilities for drug discovery and developmental studies. The facility houses over 50,000 zebrafish and supports large-scale behavioral screens.

Clinical Research Infrastructure

BCM's clinical research capabilities include:

Baylor St. Luke's Medical Center: Academic medical center with dedicated memory disorders and movement disorders clinics. Over 10,000 patient visits annually for neurodegenerative disease evaluation and management.

Michael E. DeBakey VA Medical Center: Partnership providing access to veteran populations for epidemiological studies and clinical trials. Over 2,000 veterans enrolled in neurodegeneration research studies.

Texas Children's Hospital: Collaborative research on pediatric neurodegenerative conditions and developmental disorders.

Data Resources and Registries

BCM Neurodegeneration Registry: Longitudinal cohort of over 5,000 participants including patients with AD, PD, ALS, FTD, and healthy controls. Annual follow-up with cognitive assessments, biomarker collection, and neuroimaging.

Texas Alzheimer's Disease Research Center (TADRC): Statewide registry with over 3,000 participants from diverse backgrounds, focusing on Hispanic and African American populations underrepresented in traditional research.

Clinical Trials Program

Active Alzheimer's Disease Trials

BCM currently hosts over 20 active AD clinical trials:

Amyloid-Targeting Therapies:

• Lecanemab (Leqembi) Phase 3 open-label extension study
• Donanemab TRAILBLAZE-ALZ 4 trial in early AD
• Novel bispecific antibody targeting both amyloid and tau

• LMTX (methylthioninium chloride) Phase 3 trial
• Anti-tau antibody for tau propagation blocking
• ASO targeting MAPT mRNA expression

• GLP-1 receptor agonist for disease modification
• Intranasal insulin for cognitive enhancement
• Targeted immune modulation approaches

• Plasma p-tau181/p-tau217 validation across diverse populations
• Novel CSF biomarker discovery using proteomics
• Digital biomarker development using smartphone and wearable devices

Parkinson's Disease Clinical Trials

The movement disorders program at BCM conducts over 15 active PD trials:

Alpha-Synuclein-Targeting:

• Cinquance (prasinostrat) antibody Phase 2 trial
• Small molecule aggregation inhibitor study
• Gene therapy for SYN1 reduction

• LRRK2 kinase inhibitor Phase 1/2 trial
• Genetic testing and counseling programs for LRRK2 carriers

• Inosine supplementation for urate elevation
• Exercise and rehabilitation intervention trials
• Novel neuroprotective small molecules

ALS and Motor Neuron Disease Trials

BCM hosts over 10 ALS clinical trials:

Disease-Modifying Therapies:

• Edaravone Phase 4 study in sporadic ALS
• Novel SOD1-targeted ASO approaches
• C9orf72-targeted gene therapy development

• Respiratory support optimization
• Nutritional intervention studies
• Communication device development

Frontotemporal Dementia Trials

Active Programs:

• MAPT-targeted ASO development
• GRN-related interventions for progranulin deficiency
• Behavioral outcome measure validation

Regional Leadership and Partnerships

Texas Medical Center Ecosystem

BCM's location in the Texas Medical Center—the world's largest medical complex—facilitates extensive collaborations:

Baylor College of Medicine Partnerships:

• Texas Children's Hospital for pediatric neuroscience
• MD Anderson Cancer Center on chemotherapy-induced cognitive impairment
• UTHealth Houston on shared research infrastructure

• Houston Methodist Research Institute on biomarker development
• UTHealth School of Public Health on epidemiological studies
• Rice University on engineering and computational approaches

National and International Collaborations

BCM maintains active research partnerships:

National Networks:

• Alzheimer's Disease Neuroimaging Initiative (ADNI)
• Accelerating Medicines Partnership for Alzheimer's Disease (AMP-AD)
• International Parkinson's Disease Genomics Consortium (IPDGC)
• ALS Consortium

• University of Cambridge (UK) on tau biology
• Karolinska Institutet (Sweden) on neurodegeneration mechanisms
• Japanese universities on aging research
• Australian institutions on biomarker development

Impact and Outcomes

Scientific Impact Metrics

Publication Output:

• Over 400 peer-reviewed publications in neurodegeneration annually
• High-impact publications in Nature, Science, Cell family journals
• Average citation impact in top decile of neuroscience journals

• Over $120 million in annual NIH funding for neuroscience research
• Major grants from NIA, NINDS, Michael J. Fox Foundation
• Substantial industry partnerships for clinical translation

Clinical Care Impact

Patient Care Statistics:

• 12,000+ annual patient visits for neurodegenerative diseases
• Comprehensive multidisciplinary care teams
• 95%+ patient satisfaction rate
• Reduced diagnostic wait times through integrated assessment pathways

Training Outcomes

Education Programs:

• 50+ predoctoral students trained annually in neuroscience
• 25+ clinical fellows completing subspecialty training per year
• Multiple trainees receiving prestigious awards and fellowships
• Alumni in leadership positions at major institutions worldwide

Diversity and Inclusion

BCM is committed to increasing diversity in neurodegeneration research:

Population Diversity:

• Hispanic/Latino representation at 30%+ in clinical studies
• African American participation exceeding 20% in research programs
• International collaborations expanding global representation

• Underrepresented minority trainees in neuroscience programs
• Faculty recruitment initiatives for diverse perspectives
• Community engagement programs in diverse neighborhoods

References